GlassScriptPhysician profile
Ahmet L Guler
NPI 1659604650
$11,878.77
in general payments reported to CMS, 2019-2025
36 companies · $4,352 in 2025
The $4,352 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,899 · 2020: $147 · 2021: $531 · 2022: $1,519 · 2023: $1,139 · 2024: $2,291 · 2025: $4,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,677 · Travel and Lodging: $3,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,676.73 |
| Travel and Lodging | $3,106.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,249.19 | 2024-2025 | Watchman Access System, Watchman, Watchman Flx |
| Medtronic Vascular, INC. | $1,619.38 | 2019 | |
| Biotronik INC. | $1,431.81 | 2019-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Impulse Dynamics (USA) INC. | $1,314.71 | 2023-2025 | Optimizer, Optimizer |
| Cvrx, INC. | $1,103.83 | 2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $444.28 | 2021-2024 | Xarelto |
| Amgen INC. | $420.25 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $416.12 | 2021-2025 | |
| Abbott Laboratories | $279.11 | 2021-2024 | Jot Dx, Amplatzer Amulet, Aveir |
| Pfizer INC. | $278.92 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.11 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $270.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $255.05 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $190.33 | 2021-2022 | |
| Mimedx Group, INC. | $183.01 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $151.96 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.70 | 2022-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $139.92 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Baxter Healthcare | $77.47 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Bardy Diagnostics, INC. | $72.94 | 2021-2022 | |
| Lilly USA, LLC | $64.15 | 2021-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $60.22 | 2022-2023 | |
| Advanced Oxygen Therapy INC. | $57.87 | 2025 | Topical Oxygen Chamber For Extremities |
| Vivaquant INC, Dba Rhythm Express | $51.75 | 2025 | Rhythm Express |
| Vital Connect, INC | $49.95 | 2022 | |
| Alnylam Pharmaceuticals INC. | $47.02 | 2022 | |
| Esperion Therapeutics, INC. | $34.19 | 2023 | Nexletol |
| Itamar Medical INC | $28.23 | 2025 | Watchpatone |
| Convatec INC. | $24.48 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.17 | 2025 | |
| Ge Healthcare | $21.15 | 2020 | |
| Integra Lifesciences Corporation | $19.12 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Scpharmaceuticals INC. | $18.77 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.36 | 2024 | Lifevest |
| Kerecis Limited | $18.03 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Amarin Pharma, INC. | $16.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmet Guler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.